Guangxi Chisage Fine Chemical Technology Co., Ltd.
000953.SZ · SHZ
Company research
Guangxi Hechi Chemical Co., Ltd (SZSE: 000953), founded in 1969 and listed on the Shenzhen Stock Exchange in December 1999, is a China-based company engaged in the research, development, production, and sale of chemical raw materials and their preparations, with operations spanning both domestic and international markets including Taiwan, India, and Finland. The company's core business lines include pharmaceutical intermediates — notably products used in anti-malarial drugs, progestational agents, and nutritional supplements — as well as the contracted processing and sales of urea under its well-known "Qunshan" brand, one of Guangxi's most recognized fertilizer brands. Originally established as the Guangxi Hechi Nitrogen Fertilizer Plant and formerly a subsidiary of China National Chemical Corporation (ChemChina), the company has evolved significantly beyond its fertilizer origins, now focusing primarily on high-value pharmaceutical intermediates alongside its traditional agricultural inputs business. Headquartered in Hechi, Guangxi Zhuang Autonomous Region, the company recently rebranded as Guangxi Chisage Fine Chemical Technology Co., Ltd. in May 2026, reflecting its strategic pivot toward specialty chemicals and pharmaceutical intermediates.
Research reports
Reviews the 2025 annual report, highlighting a sharp headline net profit decline driven by the absence of large one-off gains from 2024, alongside strong growth in underlying earnings and operating cash flow; it discusses the shift toward higher-margin pharmaceutical intermediates, key pressures on the traditional chemical and urea business, and major risks including policy changes, market demand volatility, and product obsolescence.
中金在线 (CNFOL) · January 26, 2026河化股份 2025 年业绩预告发布：净利润下滑系基数效应，扣非增长彰显主业韧性Analyzes the 2025 earnings guidance by framing the reported net profit decline as a base‑effect from large 2024 non‑recurring gains, while emphasizing strong growth in adjusted (ex‑non‑recurring) profit, improved margins, cash‑flow strength, and a resilient two‑pillar structure with the Chongqing Nansong pharmaceutical intermediates arm as the main profit engine; it also notes cost‑control efforts, balance‑sheet deleveraging, and the company’s strategic focus on new product R&D to mitigate demand and policy risks.
中国证券报·中证网 / 东方财富 · January 26, 2026河化股份：2025年净利同比预降88.64%-92.43%Summarizes the 2025 profit warning, explaining that headline net income is expected to fall sharply due to the absence of roughly 76 million RMB in non‑recurring gains booked in 2024, while adjusted net profit is projected to grow meaningfully; it provides valuation context via high current P/E, P/B, and P/S multiples, outlines the company’s reliance on pharmaceutical intermediates and urea processing, and flags that future performance will be sensitive to non‑recurring items, market conditions, and execution of cost‑control measures.